Results regarding Baxdrostat were presented at the ESC Congress 2025 and published in the New England Journal of Medicine.
1 report, 1 independent
Updated Aug 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Results regarding Baxdrostat were presented at the ESC Congress 2025 and published in the New England Journal of Medicine.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
European Society of Cardiology
non-profit knowledge-based professional association
Related events
- Tenax Therapeutics presented findings and announced results at the European Society of Cardiology Congress 2026.
- BridgeBio presented data at the annual ESC Congress in 2026, with Marianna Fontana affiliated with UCL.
- Trial results regarding HeartFlow Inc. were presented at the ESC Congress, focusing on how AI technology supports the guidelines of the American College of Cardiology.
- Research addressing limitations in ESC guidelines was presented, involving Aalborg University and Aamir Mahmood.
- GE Healthcare unveiled new cardiovascular ultrasound systems at the ESC Congress in Munich.
Coverage
Newest first; wire copies grouped- Business WireBaxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial Baxdrosta